Oligodendrogliomas: An update on basic and clinical research

Current Neurology and Neuroscience Reports

Volumn 3, Issue 3, 2003, Pages 223-228

  Sanson, Marc ^a   Aguirre Cruz, Lucinda ^a   Cartalat Carel, Stéphanie ^a   Hoang Xuan, Khe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; TUMOR MARKER; VINCRISTINE;

CELL LINEAGE; CHEMOSENSITIVITY; CHEMOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG PENETRATION; DRUG TISSUE LEVEL; GENETIC MARKER; GLIOMA; HISTOPATHOLOGY; HUMAN; MORPHOLOGY; OLIGODENDROGLIOMA; PREDICTION; PROGNOSIS; RADIOTHERAPY; REVIEW; SURGICAL TECHNIQUE; TREATMENT INDICATION; TUMOR CLASSIFICATION; ANIMAL; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; MEDICAL RESEARCH;

ANIMALS; BIOMEDICAL RESEARCH; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; OLIGODENDROGLIOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 0038605537     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-003-0082-1     Document Type: Review

References (56)

1. Cairncross JG, MacDonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23:360-364.
2. Kleihues P, Louis DN, Scheithauer BW, et al.: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215-225.
3. Daumas-Duport C, Varlet P, Tucker ML, et al.: Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 1997, 34:37-59.
4. Burger PC: What is an oligodendroglioma? Brain Pathol 2002, 12:257-259.
5. Coons SW, Johnson PC, Scheithauer BW, et al.: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381-1393.
6. Daumas-Duport C, Tucker ML, Kolles H, et al.: Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol 1997, 34:61-78.
7. Donahue B, Scott CB, Nelson JS, et al.: Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 1997, 38:911-914.
8. He J, Mokhtari K, Sanson M, et al.: Glioblastomas with an oligodendroglial componant: a pathological and molecular study. J Neuropathol Exp Neurol 2001, 60:863-871.
9. Pringle NP, Yu WP, Howell M, et al.: Fgfr3 expression by astrocytes and their precursors: evidence that astrocytes and oligodendrocytes originate in distinct neuroepithelial domains. Development 2003, 130:93-102.
10. Dai C, Celestino JC, Okada Y, et al.: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001, 15:1913-25.
11. Popko B, Pearl DK, Walker DM, et al.: Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 2002, 61:329-338.
12. Shoshan Y, Nishiyama A, Chang A, et al.: Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A 1999, 96:10361-10366.
13. Lu QR, Yuk D, Alberta JA, et al.: Sonic hedgehog-regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 2000, 25:317-329.
14. Zhou Q, Wang S, Anderson DJ: Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 2000, 25:331-343.
15. Lu QR, Park JK, Noll E, et al.: Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U SA 2001, 98:10851-10856.
16. Marie Y, Sanson M, Mokhtari K, et al.: OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001, 358:298-300.
17. Ino Y, Betensky RA, Zlatescu MC, et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7:839-845.
18. Sasaki H, Zlatescu MC, Betensky RA, et al.: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 2002, 61:58-63.
19. Bello MJ, Leone PE, Vaquero J, et al.: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995, 64:207-210.
20. Smith JS, Alderete B, Minn Y, et al.: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999, 18:4144-4152.
21. Husemann K, Wolter M, Buschges R, et al.: Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999, 58:1041-1050.
22. Smith JS, Tachibana I, Lee HK, et al.: Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000, 29:16-25.
23. Sanson M, Leuraud P, Marie Y, et al.: Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas. Ann Neurol 2002, 52:105-107.
24. Sasaki H, Zlatescu MC, Betensky RA, et al.: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001, 159:359-367.
25. Sanson M, Leuraud P, Aguirre-Cruz L, et al.: Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 2002, 97:1397-1401.
26. Hoang-Xuan K, He J, Huguet S, et al.: Molecular heterogeneity of oligodendrogliomas suggest alternative pathways in tumoral progression. Neurology 2001, 57:1278-1281.
27. Kraus JA, Koopmann J, Kaskel P, et al.: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995, 54:91-95.
28. Maintz D, Fiedler K, Koopmann J, et al.: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997, 56:1098-1104.
29. Yahanda AM, Bruner JM, Donehower LA, Morrison RS: Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 1995, 15:4249-4259.
30. Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479.
31. Smith JS, Perry A, Borell TJ, et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636-640.
32. Bauman GS, Ino Y, Ueki K, et al.: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000, 48:825-830.
33. Zlatescu MC, Tehrani Yazdi A, Sasaki H, et al.: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001, 61:6713-7615.
34. Mueller W, Hartmann C, Hoffmann A, et al.: Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002, 161:313-319.
35. Spassky N, Heydon K, Mangatal A, et al.: Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFRalpha signaling. Development 2001, 128:4993-5004.
36. Mukasa A, Ueki K, Matsumoto S, et al.: Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002, 21:3961-3968.
37. Watson MA, Perry A, Budhjara V, et al.: Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 2001, 61:1825-1829.
38. Karim AB, Afra D, Cornu P, et al.: Randomized trial on the efficacy of radiotherapy for cerebral low grade glioma in the adult: EORTC study 22845 with medical Research Council study BR04: an interim analysis. Int J Radiat Oncol Biol Phys 2002, 52:316-324.
39. Karim AB, Maat B, Hatlevoll R, et al.: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996, 36:549-556.
40. Shaw E, Arussell R, Scheithauer B, et al.: Prospective randomized trial of low versus high dose radiation therapy in adults with supratentorial low grade glioma: initial report of the NCCTG/RTOG/ECOG study. J Clin Oncol 2002, 20:2267-2276.
41. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203-207.
42. Buckner J: Primary chemotherapy (PCV) in low grade glioma phase II trial [abstract]. J Neuro-Oncol 1999, 35:S12.
43. Soffietti R: PCV chemotherapy for newly diagnosed low grade oligodendroglial tumors: a phase II study [abstract]. Neurooncology 2001, 34:400.
44. Viviers L: A phase II trial of primary chemotherapy with temozolomide in patients with low grade gliomas. Neuro-oncology 2000, 2(suppl 1):S43.
45. Olson JD, Riedel E, DeAngelis LM: Long term outcome of low grade oligodendroglioma and mixed glioma. Neurology 2000, 54:1442-1448.
46. Walker MD, Alexander E Jr, Hunt WF, et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
47. Fortin D, Cairncross G, Hammond RR: Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999, 45:1279-1291.
48. Glass J, Hochberg FH, Gruber ML, et al.: The treatment of oligodendrogliomas and mixed oligodendrogliomas with PCV chemotherapy. J Neurosurg 1992, 76:741-745.
49. Cairncross G, Macdonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994, 12:2013-2021.
50. Kim L, Hochberg FH, Thornton AF, et al.: PCV chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996, 85:602-607.
51. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43:1066-1073.
52. Van den Bent MJ, Kros JM, Heimans JJ, et al.: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 1998, 51:1140-1145.
53. Streffer J, Schabet M, Bamberg M, et al.: A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 2000, 247:297-302.
54. Chinot OL, Honoré S, Dufour H, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449-2445.
55. Van den Bent MJ, Keime-Guibert F, Brandes AA, et al.: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001, 57:340-342.
56. Shaw EG, Scheithauer BW, O'Fallon JR: Supratentorial gliomas: a comparative study by grade and histologic type. J Neuro-Oncol 1997, 31:273-278.